Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs

Belief in tau — both as a target and surrogate endpoint — for Alzheimer’s is building among leaders in the field. On the latest BioCentury This Week podcast, Executive Editor Selina Koch discusses how tau could be reaching a tipping point. Also on this week’s episode, Washington Editor Steve Usdin details how political moves have begun to intrude into the Trump administration’s regulation of vaccines, a topic that’s also taken up by Phil Krause and Luciana Borio in a BioCentury Guest Commentary published Monday. BioCentury’s editors then discuss delays for drug regulation at FDA, Merck KGaA's $3.9 billion deal to acquire Springworks, and why biotech IPOs could soon have a moment in Hong Kong. This episode of BioCentury This Week podcast is sponsored by RemeGen.View full story: https://www.biocentury.com/article/655780#biotech #biopharma #pharma #lifescience #alzheimers #RandD #DrugDevelopment #IPO00:01 - Sponsor Message: RemeGen Co.02:06 - Tau Time for Alzheimer's13:10 - Vaccine Drama at FDA23:32 - Merck KGaA's SpringWorks Buy24:52 - Hong Kong Biotech IPOsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text